Clinical Trial Update: Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing AKST4290 for Parkinson's disease patients on stable dopaminergic therapy has completed and posted results in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• AKST4290

Snippet

Sponsor: Alkahest, Inc. | Conditions: Parkinson Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-10-10